» Articles » PMID: 37686057

Design of Cyclic Peptides Targeting Protein-Protein Interactions Using AlphaFold

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Sep 9
PMID 37686057
Authors
Affiliations
Soon will be listed here.
Abstract

More than 930,000 protein-protein interactions (PPIs) have been identified in recent years, but their physicochemical properties differ from conventional drug targets, complicating the use of conventional small molecules as modalities. Cyclic peptides are a promising modality for targeting PPIs, but it is difficult to predict the structure of a target protein-cyclic peptide complex or to design a cyclic peptide sequence that binds to the target protein using computational methods. Recently, AlphaFold with a cyclic offset has enabled predicting the structure of cyclic peptides, thereby enabling de novo cyclic peptide designs. We developed a cyclic peptide complex offset to enable the structural prediction of target proteins and cyclic peptide complexes and found AlphaFold2 with a cyclic peptide complex offset can predict structures with high accuracy. We also applied the cyclic peptide complex offset to the binder hallucination protocol of AfDesign, a de novo protein design method using AlphaFold, and we could design a high predicted local-distance difference test and lower separated binding energy per unit interface area than the native MDM2/p53 structure. Furthermore, the method was applied to 12 other protein-peptide complexes and one protein-protein complex. Our approach shows that it is possible to design putative cyclic peptide sequences targeting PPI.

Citing Articles

Exploring a Potential Optimization Route for Peptide Ligands of the Sam Domain from the Lipid Phosphatase Ship2.

Vincenzi M, Mercurio F, La Manna S, Palumbo R, Pirone L, Marasco D Int J Mol Sci. 2024; 25(19).

PMID: 39408946 PMC: 11476629. DOI: 10.3390/ijms251910616.


CycPeptMP: enhancing membrane permeability prediction of cyclic peptides with multi-level molecular features and data augmentation.

Li J, Yanagisawa K, Akiyama Y Brief Bioinform. 2024; 25(5).

PMID: 39210505 PMC: 11361855. DOI: 10.1093/bib/bbae417.


AI-Assisted Rational Design and Activity Prediction of Biological Elements for Optimizing Transcription-Factor-Based Biosensors.

Ding N, Yuan Z, Ma Z, Wu Y, Yin L Molecules. 2024; 29(15).

PMID: 39124917 PMC: 11313831. DOI: 10.3390/molecules29153512.


Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment.

Zeng Q, Hu H, Huang Z, Guo A, Lu S, Tong W Front Mol Biosci. 2024; 11:1413214.

PMID: 38919748 PMC: 11196408. DOI: 10.3389/fmolb.2024.1413214.


Leveraging machine learning models for peptide-protein interaction prediction.

Yin S, Mi X, Shukla D RSC Chem Biol. 2024; 5(5):401-417.

PMID: 38725911 PMC: 11078210. DOI: 10.1039/d3cb00208j.


References
1.
Word J, Lovell S, Richardson J, Richardson D . Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol. 1999; 285(4):1735-47. DOI: 10.1006/jmbi.1998.2401. View

2.
Peccati F, Alunno-Rufini S, Jimenez-Oses G . Accurate Prediction of Enzyme Thermostabilization with Rosetta Using AlphaFold Ensembles. J Chem Inf Model. 2023; 63(3):898-909. PMC: 9930118. DOI: 10.1021/acs.jcim.2c01083. View

3.
Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D . Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-49. DOI: 10.1021/jm0306430. View

4.
Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z . PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front Pharmacol. 2021; 12:731798. PMC: 8440961. DOI: 10.3389/fphar.2021.731798. View

5.
Anishchenko I, Pellock S, Chidyausiku T, Ramelot T, Ovchinnikov S, Hao J . De novo protein design by deep network hallucination. Nature. 2021; 600(7889):547-552. PMC: 9293396. DOI: 10.1038/s41586-021-04184-w. View